

## riTUXimab-HyperCVAD Therapy (MCL) – Part A

### INDICATIONS FOR USE:

INDICATION	ICD10	Regimen Code	*Reimbursement Status
Treatment of adult patients with mantle cell lymphoma	C83	00466a	Hospital

\*If the reimbursement status<sup>1</sup> is not defined, the indication has yet to be assessed through the formal HSE reimbursement process.

### TREATMENT:

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patient's individual clinical circumstances.

Treatment is administered as described in the treatment table below.

Treatment with R-HyperCVAD (Part A) (cycle 1, 3, 5, 7) is alternated every 21 days with treatment with R-Methotrexate Cytarabine (Part B)\* (cycle 2, 4, 6, 8) for a total of 8 cycles or until disease progression or unacceptable toxicity develops.

\*See NCCP Regimen 00467 R-Methotrexate Cytarabine Therapy (MCL)-Part B for details

Cycle 1	Cycle 2	Cycle 3	Cycle 4	Cycle 5	Cycle 6	Cycle 7	Cycle 8
R-HyperCVAD	R-MA	R-HyperCVAD	R-MA	R-HyperCVAD	R-MA	R-HyperCVAD	R-MA

Facilities to treat anaphylaxis MUST be present when the chemotherapy is administered.

Day	Drug	Dose	Route	Diluent and Rate
1	Methotrexate	12.5mg	Intrathecal <sup>1</sup>	
2,3,4,5, 12,13,14,15	Dexamethasone	40mg	PO or IV	
2	riTUXimab	375mg/m <sup>2</sup>	IV infusion <sup>2</sup> Observe post infusion	500ml 0.9% sodium chloride at a maximum rate of 400mg/hr <sup>2</sup>
2,3,4	Mesna	250mg/m <sup>2</sup>	IV bolus	Immediately before the <b>AM</b> dose of cyclophosphamide infusion
2,3,4	Cyclophosphamide	300mg/m <sup>2</sup> ( <b>AM Dose</b> )	IV infusion	500ml 0.9% NaCl over 3 hours
2,3,4	Mesna	250mg/m <sup>2</sup>	IV bolus	3hours after the start of <b>AM</b> dose of cyclophosphamide infusion
2,3,4	Mesna	250mg/m <sup>2</sup>	IV bolus	Immediately before the <b>PM</b> dose of cyclophosphamide infusion
2,3,4	Cyclophosphamide	300mg/m <sup>2</sup> ( <b>PM Dose</b> ) To start 12 hours after start of AM dose	IV infusion	500ml 0.9% NaCl over 3 hours
2,3,4	Mesna	250mg/m <sup>2</sup>	IV bolus	3hours after the start of <b>PM</b> dose of cyclophosphamide infusion

NCCP Regimen: R-HyperCVAD Therapy (MCL)-Part A	Published: 15/02/2019 Review: 15/02/2021	Version number: 1
Tumour Group: Lymphoma NCCP Regimen Code: 00466	IHS Contributors: Dr Anne Fortune	Page 1 of 8

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check [www.hse.ie/NCCPchemoregimens](http://www.hse.ie/NCCPchemoregimens)

5, 12	vinCRIStine <sup>3</sup> (max 2mg)	1.4mg/m <sup>2</sup>	IV infusion	50ml 0.9% NaCl over 15min
5	DOXOrubicin <sup>4</sup>	50mg/m <sup>2</sup>	IV infusion	1000ml 0.9% NaCl over 24 hours ( <b>PM dose</b> start 12 hours after end of last cyclophosphamide infusion)
7 onwards	G-CSF (round to nearest whole syringe)	5mcg/kg	sc	Until ANC>1 x 10 <sup>9</sup> /L for 2 consecutive days
<sup>1</sup> Refer to NCCP Guidance on the Safe Use of Intrathecal Chemotherapy in the Treatment of Cancer <a href="https://www.hse.ie/eng/services/list/5/cancer/profinfo/medonc/safetyreview/itcguidance.pdf">https://www.hse.ie/eng/services/list/5/cancer/profinfo/medonc/safetyreview/itcguidance.pdf</a>				
<sup>2</sup> See table 1:Guidance for administration of ritUXimab				
<sup>3</sup> vinCRIStine is a neurotoxic chemotherapeutic agent. Refer to NCCP Guidance on the Safe Use of Neurotoxic drugs (including Vinca Alkaloids) in the treatment of cancer <a href="https://www.hse.ie/eng/services/list/5/cancer/profinfo/medonc/safetyreview/neurotoxicguidance.pdf">https://www.hse.ie/eng/services/list/5/cancer/profinfo/medonc/safetyreview/neurotoxicguidance.pdf</a>				
<sup>4</sup> Lifetime cumulative dose of DOXOrubicin is 450mg/m <sup>2</sup> <b>In establishing the maximal cumulative dose of an anthracycline, consideration should be given to the risk factors outlined below<sup>ii</sup> and to the age of the patient.</b>				

**Table 1: Guidance for administration of Rituximab**

<p>The recommended initial rate for infusion is 50 mg/hr; after the first 30 minutes, it can be escalated in 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr. Subsequent infusions can be infused at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30 minute intervals, to a maximum of 400 mg/hr. Development of an allergic reaction may require a slower infusion rate. See Hypersensitivity/Infusion reactions under Adverse Effects/Regimen Specific Complications below. Any deviation from the advised infusion rate should be noted in local policies.</p>
<p>Recommended Observation period: Patients should be observed for at least six hours after the start of the first infusion and for two hours after the start of the subsequent infusions for symptoms like fever and chills or other infusion-related symptoms. Any deviation should be noted in local policies</p>
<p><b>Rituximab should be diluted to a final concentration of 1-4mg/ml.</b></p>
<p>Rapid rate infusion schedule<sup>iii</sup> See NCCP guidance <a href="#">here</a> If patients did not experience a serious infusion related reaction with their first or subsequent infusions of a dose of rituximab administered over the standard infusion schedule, a more rapid infusion can be administered for second and subsequent infusions using the same concentration as in previous infusions. Initiate at a rate of 20% of the total dose for the first 30 minutes and then 80% of the dose for the next 60 minutes (total infusion time of 90 minutes). If the more rapid infusion is tolerated, this infusion schedule can be used when administering subsequent infusions. Patients who have clinically significant cardiovascular disease, including arrhythmias, or previous serious infusion reactions to any prior biologic therapy or to rituximab, should not be administered the more rapid infusion.</p>

## ELIGIBILITY:

- Indication as above
- ECOG status 0-2
- LVEF ≥ 50%
  - Where a patient's LVEF <50%, consideration could be given to the administration of doxorubicin over 48hours at the discretion of the treating consultant.

NCCP Regimen: R-HyperCVAD Therapy (MCL)-Part A	Published: 15/02/2019 Review: 15/02/2021	Version number: 1
Tumour Group: Lymphoma NCCP Regimen Code: 00466	IHS Contributors: Dr Anne Fortune	Page 2 of 8

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

*This information is valid only on the day of printing, for any updates please check [www.hse.ie/NCCPchemoregimens](http://www.hse.ie/NCCPchemoregimens)*

## EXCLUSIONS:

- Hypersensitivity to ritUXimab, cyclophosphamide, DOXOrubicin, vinCRiStine, cytarabine or any of the excipients
- Breast feeding
- Pregnancy

## PRESCRIPTIVE AUTHORITY:

The treatment plan must be initiated by a Consultant Medical Oncologist or Consultant Haematologist working in the area of haematological malignancies.

## TESTS:

### Baseline tests:

- FBC, renal and liver profile
- Uric acid
- ECG
- Cardiac function using MUGA or ECHO (LVEF  $\geq$ 50% to administer DOXOrubicin)
- Virology screen -Hepatitis B (HBsAg, HBcoreAb) & C, HIV.

\*Hepatitis B reactivation: See adverse events/ Regimen specific complications

### Regular tests:

- FBC, renal and liver profile prior to each cycle and as clinically indicated
- Assessment of peripheral neuropathy status prior to each cycle
- Cardiac function if clinically indicated

### Disease monitoring:

Disease monitoring should be in line with the patient's treatment plan and any other test/s as directed by the supervising Consultant.

## DOSE MODIFICATIONS:

- Any dose modification should be discussed with a Consultant
- Note: Patients may have their first dose of rituximab delayed or omitted at the discretion of the prescribing Consultant if there is concern for tumour lysis syndrome or cytokine release syndrome.

## Haematological:

**Table 1: Haematological criteria for administration of R-Hyper-CVAD**

ANC ( x $10^9$ /L)		Platelets ( x $10^9$ /L)	
>1*	and	60*	Cycle proceeds. Alternates with ritUXimab-Methotrexate Cytarabine Therapy (MCL) Part B (NCCP Regimen 00467)

\*G-CSF has been discontinued for at least 24 hours

NCCP Regimen: R-HyperCVAD Therapy (MCL)-Part A	Published: 15/02/2019 Review: 15/02/2021	Version number: 1
Tumour Group: Lymphoma NCCP Regimen Code: 00466	IHS Contributors: Dr Anne Fortune	Page 3 of 8

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

*This information is valid only on the day of printing, for any updates please check [www.hse.ie/NCCPchemoregimens](http://www.hse.ie/NCCPchemoregimens)*

## Renal and Hepatic Impairment:

**Table 2: Recommended dose modifications based on renal and hepatic impairment**

Drug	Renal Impairment	Hepatic Impairment			
riTUXimab	Probably no dose reduction necessary	Probably no dose reduction necessary			
DOXOrubicin	No dose reduction required. Clinical decision in severe renal impairment	<b>Bilirubin (micromol/L)</b>	<b>Dose</b>		
		20-51	50%		
		51-85	25%		
		>85	omit		
		If AST 2-3 x normal, give 75% dose. If AST >3x ULN, give 50% dose			
Cyclophosphamide	<b>GFR (ml/min)</b>	<b>Dose</b>			
	>20	100%			
	10-20	75%			
	<10	50%			
vinCRISTine	No dose reduction required	<b>Bilirubin (micromol/L)</b>		<b>AST/ALT (Units)</b>	<b>Dose</b>
		26-51	or	60-180	50%
		>51	and	N	50%
		>51	and	>180	Omit

## Neurotoxicity:

**Table 3: Recommended dose modification of vincristine based on neurotoxicity (CTCAE v 4.0)**

Symptom	Dose of Vincristine
Grade 1	100%
Grade 2	Hold until recovery, then reduce dose by 50 %
Grade 3,4	Omit

**Table 4: Dose modification schedule of rituximab based on adverse events**

Adverse reactions	Discontinue	Recommended dose modification
Severe infusion related reaction (e.g dyspnoea, bronchospasm, hypotension or hypoxia) First occurrence		Interrupt infusion immediately. Evaluate for cytokine release/tumour lysis syndrome (appropriate laboratory tests) and pulmonary infiltration (chest x -ray). Infusion may be restarted on resolution of all symptoms, normalisation of laboratory values and chest x-ray findings at no more than one-half the previous rate.
Second occurrence	Consider discontinuing treatment	Consider coverage with steroids for those who are not already receiving steroids.
Mild or moderate infusion-related reaction		Reduce rate of infusion. The infusion rate may be increased upon improvement of symptoms

NCCP Regimen: R-HyperCVAD Therapy (MCL)-Part A	Published: 15/02/2019 Review: 15/02/2021	Version number: 1
Tumour Group: Lymphoma NCCP Regimen Code: 00466	IHS Contributors: Dr Anne Fortune	Page 4 of 8
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		

## SUPPORTIVE CARE:

**EMETOGENIC POTENTIAL:** High risk. (Refer to local policy)

### PREMEDICATIONS:

Premedication consisting of an anti-pyretic and an anti-histamine should always be administered before each infusion of rituximab.

**Table 5: Suggested pre-medications prior to riTUXimab infusion:**

Drugs	Dose	Route
Paracetamol	1g	PO 60minutes prior to rituximab infusion
Chlorpheniramine	10mg	IV bolus 60minutes prior to rituximab infusion
Ensure glucocorticoid component of the treatment regimen (Dexamethasone 40mg) is given at least 30 minutes prior to rituximab infusion		

### OTHER SUPPORTIVE CARE:

- Tumour lysis syndrome prophylaxis (Refer to local policy)
- Proton pump Inhibitor (Refer to local policy). If a PPI is used it should be held before the administration of Methotrexate.
- PJP prophylaxis (Refer to local policy) If co-trimoxazole is used it needs to be discontinued at least one week prior to commencing (riTUXimab-Methotrexate-Cytarabine (Part B) cycle NCCP Regimen 00467a)
- Anti-viral prophylaxis (Refer to local policy)
- Anti-fungal prophylaxis Avoid the concurrent use of azoles and vinCRiStine (5) (Refer to local policy)

## ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

- **Hypersensitivity/Infusion Reactions:** Close monitoring is required throughout the first infusion of Rituximab. (Refer to local policy). RiTUXimab can cause allergic type reactions during the IV infusion such as hypotension, wheezing, rash, flushing, pruritis, sneezing, cough, fever or faintness. Monitor infusion of etoposide for the first 15 minutes for signs of hypotension
- **Cardiac Toxicity:** Patients with a history of cardiac disease and/or cardiotoxic chemotherapy should be monitored closely while on riTUXimab. Doxorubicin is cardiotoxic and must be used with caution, if at all, in patients with cardiac dysfunction.
- **Neuropathy:** vincristine may cause peripheral neuropathy which is dose related and cumulative, requiring monitoring before each dose is administered. The presence of pre-existing neuropathies or previous treatment with other neurotoxic drugs may increase risk of peripheral neuropathy. Patients with mild peripheral neuropathy can usually continue to receive full doses of vincristine, but when symptoms increase in severity and interfere with neurologic function, dose reduction or discontinuation of the drug may be necessary. The natural history following discontinuation of treatment is gradual improvement, which may

NCCP Regimen: R-HyperCVAD Therapy (MCL)-Part A	Published: 15/02/2019 Review: 15/02/2021	Version number: 1
Tumour Group: Lymphoma NCCP Regimen Code: 00466	IHS Contributors: Dr Anne Fortune	Page 5 of 8

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check [www.hse.ie/NCCPchemoregimens](http://www.hse.ie/NCCPchemoregimens)

take up to several months. A routine prophylactic regimen against constipation is recommended for all patients receiving vincristine sulphate. Paralytic ileus may occur. The ileus will reverse itself upon temporary discontinuance of vincristine and with symptomatic care.

- **Extravasation:** DOXOrubicin and vinCRISTine cause pain and possible tissue necrosis if extravasated (refer to local policy).
- **Hepatitis B Reactivation:** All lymphoma patients should be tested for both HBsAg and HB core Ab as per local policy. If either test is positive, such patients should be treated with lamivudine 100 mg/day orally, for the entire duration of chemotherapy and for six months afterwards. Such patients should also be monitored with frequent liver function tests and hepatitis B virus DNA at least every two months. If the hepatitis B virus DNA level rises during this monitoring, management should be reviewed with an appropriate specialist with experience managing hepatitis and consideration given to stopping chemotherapy.

## DRUG INTERACTIONS:

- Antihypertensives: Additive effect of hypotension during ritUXimab infusion. Consider withholding antihypertensive 12 hours before and during rituximab infusion.
- DOXOrubicin cardiotoxicity is enhanced by previous or concurrent use of other anthracyclines, or other potentially cardiotoxic drugs (e.g. 5-FU, cyclophosphamide or paclitaxel) or with products affecting cardiac function (e.g. calcium antagonists).
- Current drug interaction databases should be consulted for more information including potential for interactions with CYP3AR inhibitors/ inducers.

## ATC CODE:

Rituximab	-	L01XC02
Cyclophosphamide	-	L01AA01
DOXOrubicin	-	L01DB01
VinCRISTine	-	L01CA02

## REFERENCES:

1. Romaguera et al. High Rate of Durable Remissions after Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma with Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine. J Clin Oncol 2005;23(28):7013-23.
2. Merli F, Luminari S et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfom. British J Haematology 2011; 156:346-353.
3. Wang M et al. Phase 2 Trial of Rituximab plus Hyper-CVAD alternating with Rituximab plus Methotrexate-Cytarabine for Reapsed or Refractory Aggressive Mantle Cell Lymphoma. Cancer 2008; 113:2734-41.
4. Thomas DA et al. Outcome with the hyper- CVAD regimen in lymphoma. Blood 2004; 104:6:1624-30.
5. NCCP | Rituximab Rapid Infusion Rate Guidance | V1 2017 available at <https://www.hse.ie/eng/services/list/5/cancer/profinfo/medonc/sactguidance/guidance%20on%20rituximab%20rapid%20infusion%20rate.pdf>

NCCP Regimen: R-HyperCVAD Therapy (MCL)-Part A	Published: 15/02/2019 Review: 15/02/2021	Version number: 1
Tumour Group: Lymphoma NCCP Regimen Code: 00466	IHS Contributors: Dr Anne Fortune	Page 6 of 8
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		

6. Dosage Adjustment for Cytotoxics in Renal Impairment January 2009; North London Cancer Network . Available at <http://londoncancer.org/media/65600/renal-impairment-dosage-adjustment-for-cytotoxics.pdf>
7. Dosage Adjustment for Cytotoxics in Hepatic Impairment January 2009;North London Cancer Network. Available at <http://londoncancer.org/media/65594/hepatic-impairment-dosage-adjustment-for-cytotoxics.pdf>
8. Vinca alkaloids + Azoles. Stockley's Drug Interactions 11<sup>th</sup> Edition
9. MabThera® Summary of Product Characteristics Accessed Feb 2018. Available at: [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Product\\_Information/human/000165/WC500025821.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000165/WC500025821.pdf)
10. Endoxana Injection 500mg Powder for Solution for Injection. Summary of Product Characteristics Accessed Feb 2018 Available at [https://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC\\_PA0167-134-003\\_13022012114117.pdf](https://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_PA0167-134-003_13022012114117.pdf)
11. Doxorubicin HCl 50mg Powder for Solution for Injection. Summary of Product Characteristics. Accessed Feb 2018 Available at [http://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC\\_PA0437-026-002\\_11062014102040.pdf](http://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_PA0437-026-002_11062014102040.pdf)
12. Vincristine Summary of Product Characteristics Accessed Feb 2018. Available at [http://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC\\_PA0437-008-005\\_10122014160104.pdf](http://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_PA0437-008-005_10122014160104.pdf)

Version	Date	Amendment	Approved By
1	24/01/2019		Dr Anne Fortune

Comments and feedback welcome at [oncologydrugs@cancercontrol.ie](mailto:oncologydrugs@cancercontrol.ie).

<sup>i</sup> ODMS – Oncology Drug Management System

CDS – Community Drug Schemes (CDS) including the High Tech arrangements of the PCRS community drug schemes

Further details on the Cancer Drug Management Programme is available at;

<http://www.hse.ie/eng/services/list/5/cancer/profinfo/medonc/cdmp/>

<sup>ii</sup> Cardiotoxicity is a risk associated with anthracycline therapy that may be manifested by early (acute) or late (delayed) effects.

Risk factors for developing anthracycline-induced cardiotoxicity include:

- high cumulative dose, previous therapy with other anthracyclines or anthracenediones
- prior or concomitant radiotherapy to the mediastinal/pericardial area

NCCP Regimen: R-HyperCVAD Therapy (MCL)-Part A	Published: 15/02/2019 Review: 15/02/2021	Version number: 1
Tumour Group: Lymphoma NCCP Regimen Code: 00466	IHS Contributors: Dr Anne Fortune	Page 7 of 8

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

*This information is valid only on the day of printing, for any updates please check [www.hse.ie/NCCPchemoregimens](http://www.hse.ie/NCCPchemoregimens)*



- pre-existing heart disease
- concomitant use of other potentially cardiotoxic drugs

In establishing the maximal cumulative dose of an anthracycline, consideration should be given to the risk factors above and to the age of the patient

iii The rapid infusion is an unlicensed means of administration of rituximab for the indications described above, in Ireland. Patient's should be informed of this and consented to treatment in line with the hospital's policy on the use of unlicensed medication and unlicensed or "off label" indications. Prescribers should be fully aware of their responsibility in communicating any relevant information to the patient and also ensuring that the unlicensed or "off label" means of administration has been acknowledged by the hospital's Drugs and Therapeutics Committee, or equivalent, in line with hospital policy.

NCCP Regimen: R-HyperCVAD Therapy (MCL)-Part A	Published: 15/02/2019 Review: 15/02/2021	Version number: 1
Tumour Group: Lymphoma NCCP Regimen Code: 00466	IHS Contributors: Dr Anne Fortune	Page 8 of 8
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		